Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research
U ‐shaped association between serum calcium and in‐hospital mortality in patients with congestive heart failure
ConclusionsOur study identifies a U-shaped association between serum calcium levels and in-hospital mortality in CHF patients, with a notable inflection point at 8.35 mg/dL. Further investigation through prospective, randomized, and controlled studies is warranted to validate the findings presented in this study. (Source: ESC Heart Failure)
Source: ESC Heart Failure - March 12, 2024 Category: Cardiology Authors: Kai Zhang,
Yu Han,
Tianyi Cai,
Fangming Gu,
Zhaoxuan Gu,
JiaYu Zhao,
Jianguo Chen,
Bowen Chen,
Min Gao,
Zhengyan Hou,
Xiaoqi Yu,
Yafang Gao,
Rui Hu,
Jinyu Xie,
Tianzhou Liu,
MaoXun Huang Tags: Original Article Source Type: research
Association between SpO2 and the risk of death in elderly T2DM patients with cerebral infarction: a retrospective cohort study
ConclusionsStriking an optimal balance is paramount, as fixating solely on lower SpO2 limits or neglecting high SpO2 levels may contribute to increased mortality rates. To mitigate mortality risk in elderly T2DM patients with cerebral infarction, we recommend maintaining SpO2 levels within the range of 94.5–96.5%. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - March 12, 2024 Category: Neurology Source Type: research
Oxidative Products of Catecholamines During Heightened Sympathetic Activity Due to Congestive Heart Failure: Possible Role of Antioxidants
(Source: International Journal of General Medicine)
Source: International Journal of General Medicine - March 11, 2024 Category: General Medicine Tags: International Journal of General Medicine Source Type: research
Left atrial myxoma with cardiogenic shock following a myocardial infarction: a case report
ConclusionThis patient ’s case of cardiogenic shock following revascularization was complicated by the identification of an atrial myxoma, which, when large enough, can obstruct blood flow through the mitral valve leading to acute mitral dynamic stenosis. This condition results in circulatory collapse due to obstruction of the left ventricle in diastole as the myxoma occludes the mitral valve. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 11, 2024 Category: General Medicine Source Type: research
Validation of self-reported cardiovascular problems in childhood cancer survivors by contacting general practitioners: feasibility and results
CONCLUSIONS: Despite excellent GP compliance, it was found unfeasible to validate self-reported cardiovascular problems via GPs because they do not serve as gatekeepers in the Swiss health care system. It is thus necessary to develop other validation methods to improve the quality of patient-reported outcomes.PMID:38459512 | DOI:10.1186/s12875-024-02322-7 (Source: Primary Care)
Source: Primary Care - March 8, 2024 Category: Primary Care Authors: Eva-Maria Hau Tom áš Sláma Stefan Essig Gisela Michel Laura Wengenroth Eva Bergstraesser Nicolas X von der Weid Christina Schindera Claudia E Kuehni Source Type: research
Validation of self-reported cardiovascular problems in childhood cancer survivors by contacting general practitioners: feasibility and results
CONCLUSIONS: Despite excellent GP compliance, it was found unfeasible to validate self-reported cardiovascular problems via GPs because they do not serve as gatekeepers in the Swiss health care system. It is thus necessary to develop other validation methods to improve the quality of patient-reported outcomes.PMID:38459512 | DOI:10.1186/s12875-024-02322-7 (Source: Primary Care)
Source: Primary Care - March 8, 2024 Category: Primary Care Authors: Eva-Maria Hau Tom áš Sláma Stefan Essig Gisela Michel Laura Wengenroth Eva Bergstraesser Nicolas X von der Weid Christina Schindera Claudia E Kuehni Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies
Haematologica. 2024 Mar 7. doi: 10.3324/haematol.2023.284622. Online ahead of print.ABSTRACTThree major directions for the global progress of adeno-associated virus (AAV) vectors for gene therapies (GT) are analyzed: a) engineering vectors to increase transgene expression; b) aligning interests of the health system with costs and challenges for pharmaceutical industry; c) refining patient eligibility criteria, and endpoints definition. Currently employed AAV vectors may cause toxicity and adverse events. Furthermore, studies in animals do not fully predict risks and clinical benefits of AAV-based GT, and animal models refl...
Source: Haematologica - March 7, 2024 Category: Hematology Authors: Giovanni Di Minno Wolfgang Miesbach Giancarlo Castaman Flora Peyvandi Source Type: research
